Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Non-Hodgkin's lymphoma affecting the testis: Is it curable with doxorubicin-based therapy?
Autore:
Visco, C; Medeiros, LJ; Mesina, OM; Rodriguez, MA; Hagemeister, FB; McLaughlin, P; Romaguera, JE; Cabanillas, F; Sarris, AH;
Indirizzi:
Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 Lymphoma & Myeloma, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 v Pathol & Lab Med, Houston, TX 77030 USA
Titolo Testata:
CLINICAL LYMPHOMA
fascicolo: 1, volume: 2, anno: 2001,
pagine: 40 - 46
SICI:
1526-9655(200106)2:1<40:NLATTI>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
LARGE-CELL LYMPHOMA; MALIGNANT-LYMPHOMA; TESTICULAR LYMPHOMA; COMBINATION CHEMOTHERAPY; INTERMEDIATE-GRADE; IMMUNOBLASTIC LYMPHOMA; SOMATIC HYPERMUTATION; NONHODGKINS LYMPHOMA; TUMOR SCORE; B-CELLS;
Keywords:
diffuse large-cell lymphoma; gonads; Burkitt's lymphoma; central nervous system; prophylactic scrotal radiation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Sarris, AH Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515Holcombe Blvd,Box 68, Houston, TX 77030 USA Univ Texas 1515 Holcombe Blvd,Box 68 Houston TX USA 77030 0 USA
Citazione:
C. Visco et al., "Non-Hodgkin's lymphoma affecting the testis: Is it curable with doxorubicin-based therapy?", CLIN LYMPHO, 2(1), 2001, pp. 40-46

Abstract

This study was designed to determine response, outcome, and patterns of failure of patients with non-Hodgkin's lymphoma who presented with a testicular mass. Consecutive patients presenting to M.D. Anderson Cancer Center between 1969 and 1999 treated with doxorubicin-based regimens and with radiotherapy and/or intrathecal therapy were considered for this study. We identified 43 patients whose median age was 61 years. Ann Arbor stage (AAS) was I in 22 patients, II in 7 patients, III in 1 patient, and IV in 13 patients. All 43 patients had intermediate-grade lymphomas according to the Working Formulation, and all 31 tumors assessed immunophenotypically were large B-cell lymphoma according to the World Health Organization classification. The International Prognostic Index score was greater than or equal to 2 in 18 patients (42%). Thirty-four patients achieved complete remission, 19 of whomrelapsed, and 5 failed initial therapy. At 10 years, progression-free survival (PFS) was 20% +/- 9% and survival was 33% +/- 9%. Progression-free survival for patients with AAS I/II vs. III/IV was 36% +/- 13% vs. 0%, respectively (P = 0.004). At 10 years, the actuarial probability of failure in thecentral nervous system was 34% +/- 9% and was 21% +/- 9% in contralateral testis. Using the intent-to-treat method, patients receiving cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), with additional scrotal radiotherapy and intrathecal methotrexate, had a 5-year PFS of 91% +/- 9% vs. 30% +/- 15% vs. 41% +/- 12% for those receiving only one or neither of these additional modalities (P = 0.053). Doxorubicin-based regimens alone appear unable to cure most patients with lymphoma involving the testis, but CHOP with prophylactic intrathecal therapy and adjuvant scrotal radiotherapy appears promising. This should be confirmed with prospective clinical trials and longer follow-up.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 06:52:52